Compare NOM & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOM | TXMD |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 21.3M |
| IPO Year | N/A | N/A |
| Metric | NOM | TXMD |
|---|---|---|
| Price | $11.25 | $1.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 65.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $269.20 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $8.52 | $0.70 |
| 52 Week High | $10.48 | $2.44 |
| Indicator | NOM | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 53.21 |
| Support Level | $11.25 | $1.62 |
| Resistance Level | $11.58 | $2.01 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 69.86 | 44.83 |
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.